March 2026 Research Update

Studies this month added a clearer real-world picture of complement blockers in aHUS: many patients stabilize, but safety monitoring remains important and outcomes can still differ by person. In children treated with eculizumab in routine care, blood and kidney measures improved, and dialysis was often stopped. In a large database of side effect reports for ravulizumab across all its uses, many reported side effects were similar to what is already known, while a few possible additional signals were also flagged, most often early after starting treatment. [1] [2]

In one pediatric hospital cohort (11 children), all children reached complete remission of the clotting-related blood vessel injury (TMA), and kidney function improved over follow-up. Children who needed dialysis at the start were able to stop dialysis during treatment, and plasma exchange or plasma infusions were stopped in all patients. Side effects in this small group were limited, and no meningococcal infections were reported there. [1]

A separate pharmacovigilance analysis of 9,090 FAERS reports involving ravulizumab (37% for generalized myasthenia gravis, 22% for PNH, a different blood disorder, and 11% for aHUS) highlighted commonly reported problems such as fatigue, headache, shortness of breath, and some eye-related symptoms. It also flagged several possible events that were not listed on the label in this analysis (including anemia and urinary tract infection), and it found that many reported events began within about 30 days. Because these are voluntary reports without proof the drug caused the event, the results mainly point to what should be watched for and studied further rather than giving firm rates of risk. [2]

For patients and caregivers, this month adds reassurance that complement-blocking treatment can line up with meaningful improvements in real-world pediatric care, while also emphasizing that side effects and infections remain part of the safety conversation. The ravulizumab report-based study is mainly an early-warning tool, not a measure of how often problems occur, but it helps clarify which symptoms are being reported most and when they tend to appear after starting treatment. What remains uncertain is how much the flagged ravulizumab signals reflect the drug itself versus the underlying illness or other medicines, and whether similar safety patterns would appear in other datasets. Taken together, these findings may matter now for understanding expected monitoring and questions to discuss, and they may matter later if the new safety signals are confirmed in stronger studies. [1] [2]

One UK multicentre study suggested that, for some people with aHUS who had been stable on eculizumab for at least 6 months, stopping treatment with careful monitoring did not lead to many serious safety events over 2 years. Relapse still happened in a subset, and it appeared more common among people with complement regulation abnormalities. The study also reported large projected cost savings when treatment was withdrawn under this structured approach. [3]

Among 28 participants who withdrew from eculizumab, 1 person met the study's primary safety outcome, and the study team concluded withdrawal was not associated with greater risk than staying on treatment within their pre-planned analysis. Relapse was observed in 4 of 17 people with complement regulation abnormalities, while 0 of 11 without an identified abnormality relapsed in this dataset. The study also reported that restarting eculizumab quickly after relapse was feasible within the study monitoring plan. [3]

For patients, this study adds practical information about a structured withdrawal-and-monitoring approach, including the idea that relapse risk may differ depending on whether a complement regulation abnormality is present. It does not mean stopping is safe for everyone, but it helps clarify that some people may remain stable off treatment for long periods when monitoring is built in. What remains uncertain is how these results apply to broader groups, since participant numbers were small and the comparison group was especially limited. This may matter now as background information for understanding ongoing research and monitoring-focused care models, and it may matter later if confirmed in larger groups. [3]

Studies looking at genetics and triggers this month reinforced a simple message: aHUS is not one single condition, and relapse risk and presentation can vary based on underlying complement-related changes. In children, certain genetic profiles were linked to relapse in a small cohort, and a common deletion (CFHR1/CFHR3) showed up repeatedly across datasets. At the same time, one lab study in mice showed that a specific C3 gene change did not trigger an aHUS-like illness under the conditions tested, highlighting that not every suspected genetic change acts the same way in every setting. [4] [5] [6]

In 21 Egyptian children followed for 12 months, about half progressed to chronic kidney disease, and relapse was more likely in those with certain genetic findings (including CFHR gene deletions and an MMUT variant). However, many children had no clear pathogenic result on whole-exome sequencing, and the study did not find a clear link between sequencing category and chronic kidney disease outcome. This helps show both the promise and the current limits of genetic testing for explaining each child's course. [4]

A separate report centered on CFHR1/CFHR3 deletion combined a single pediatric case with analyses of two aHUS cohorts, finding the deletion was more frequent in aHUS patients than in controls and was linked with younger age at onset. The authors also described lab testing suggesting CFHR1/CFHR3-deficient plasma had less protective activity in a complement-related assay. Together, this supports CFHR1/CFHR3 deletion as a meaningful risk factor in at least some populations, while not explaining every case on its own. [5]

In a mouse model carrying the C3 p.Ile1157Thr variant (a change discussed in human aHUS genetics), the animals developed normally and did not develop an aHUS-like illness even when exposed to an inflammatory stressor. Even when combined with Adamts13 deficiency, the mice remained asymptomatic without signs of excess C3 activation. This suggests that additional factors may be required for disease, and it also shows that animal results may not fully mirror human risk. [6]

For patients and caregivers, these studies help clarify why two people with aHUS can have very different courses, including differences in relapse risk and age at onset. The genetic findings around CFHR1/CFHR3 deletion add weight to the idea that some inherited changes raise susceptibility, but they also show that many patients will not have a single clear genetic answer. The mouse study matters mainly as early research: it reminds us that a genetic change discussed in humans may not cause disease by itself, and that triggers and additional background factors likely play a role. What remains uncertain is how to translate any one genetic result into a reliable prediction for an individual person, especially across different countries and testing access. [4] [5] [6]

This month’s case reports showed how widely aHUS can present, including after infection-related kidney inflammation, after kidney retransplantation, and with heart involvement during a hypertensive crisis. Across these individual stories, eculizumab was followed by rapid improvement in blood markers and, in several cases, improvement in organ function. The cases also illustrate that kidney recovery is not guaranteed, especially when injury is severe or treatment is delayed. [7] [8] [9] [10]

In one adult case with acute cardiogenic dysfunction, starting eculizumab after an administrative delay was followed by clinical stabilization and full recovery of heart function by 6 months, while kidney failure remained dialysis-dependent. In another case after kidney retransplantation, a short course of eculizumab was followed by sustained improvement in blood and kidney lab measures with preserved transplant function. These reports highlight both potential reversibility in some organs and the possibility of lasting kidney damage in others. [7] [8]

In a 4-year-old with post-infectious glomerulonephritis who developed complement-mediated aHUS, eculizumab was followed by rapid normalization of blood counts and recovery of kidney function, with genetic testing indicating susceptibility (CFHR1/CFHR3 and CD46 changes). Another adult case with a pathogenic CD46 mutation did not improve with plasma exchange but improved quickly after eculizumab, and a later relapse years later again responded to eculizumab. Together, these cases underline that genetic susceptibility and triggers can matter, and that response can be seen even when earlier approaches do not help. [9] [10]

For patients, case reports mainly add understanding rather than changing what is known from larger studies. They help clarify that aHUS can show up in unexpected settings, including after infections or around transplantation, and that symptoms outside the kidneys can be part of the picture. They also show that some individuals have rapid improvement in blood tests after eculizumab, while kidney outcomes can range from recovery to ongoing dialysis. What remains uncertain is how often these patterns occur, because single-patient reports cannot predict what will happen for others. [7] [8] [9] [10]

A meta-analysis of real-world observational cohorts reported that plasma therapy and complement inhibitors had similar overall effectiveness and safety in aHUS, with one consistent difference: relapses were lower with complement inhibitors. When the results were split by age, differences were more visible in children than in adults, but the evidence came from observational data rather than head-to-head trials. This adds perspective on why complement inhibitors are often discussed in relapse prevention, while also showing that outcomes are not identical across all groups. [11]

In the combined analysis, relapse was reported as 0% with complement inhibitors versus 15.5% with plasma therapy. In children, complement inhibitor therapy was linked with lower rates of chronic kidney disease and death compared with plasma therapy in these cohorts, while adult outcomes looked more similar between approaches. In people who were positive for anti-factor H antibodies (an immune marker linked with complement), complement inhibitors were linked with higher kidney remission in that subgroup. [11]

For patients and caregivers, this review helps clarify what has been seen across routine-care cohorts: relapse may be less common with complement inhibitors, and some pediatric outcomes looked better in those datasets. Because the data were observational, the findings cannot prove one treatment caused better outcomes, but they do help explain why relapse prevention is a frequent focus in complement inhibitor research. The subgroup findings (such as anti-factor H antibody positivity) also reinforce that aHUS is biologically diverse, and results can differ across patient groups. What remains uncertain is how much of the pediatric difference reflects treatment choice versus other factors like illness severity, timing of treatment, and access to care. [11]